Trending Topic

3D rendered Medical Illustration of Male Anatomy - Rectal Cancer.
14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Gabriel Valagni, Nkafu Bechem Ndemazie, Tiago Biachi de Castria

Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 It was first identified by Callahan et al. in 1996 as an active impurity in the herbicide trifluralin, which […]

Microwave Ablation of Lung Tumours – Clinical Update

Thomas J Vogl, Nagy Naguib, Tatjana Gruber-Rouh, Nour-Eldin Abdelrehim Nour-Eldin
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: May 15th 2012 European Oncology & Haematology, 2012;8(3):192-5 DOI: https://doi.org/10.17925/EOH.2012.08.3.192
Select a Section…
1

Abstract

Overview

Thermal ablation offers an intriguing therapeutic option to improve local tumour control and survival in patients with early-stage non-small cell lung cancer or patients with limited metastatic disease from non-lung primaries who are not candidates for surgery, either because of poor cardiopulmonary reserve, anatomic constraints limiting resection, failure of traditional therapies, or refusal of operative approaches. The new field of interventional oncology needs adequate knowledge of the therapeutic tools, advantages and limitations of each method, when and how to apply them, as well as of the new integrative protocols that improve their efficacy. This article provides a clinical review of the role of microwave ablation therapy of primary and metastatic tumours.

Keywords

Microwave, ablation, therapy, lung tumour, metastases

2

Article

Lung cancer remains the leading cause of cancer death in the US, accounting for an estimated 29 % of cancer deaths in 2009. Pneumonectomy or lobectomy with hilar and mediastinal lymph node sampling is the gold standard treatment and offers the best option for curing stage 1/2 non-small cell lung cancer (NSCLC),1–5 Unfortunately, only 15 % of patients present with stage 1/2 disease, and many of these do not meet the pulmonary physiologic criteria for lobar resection. In addition to lung cancer, pulmonary metastases are present in 25–30 % of patients dying from all types of cancer. For some patients with oligometastatic pulmonary disease, metastectomy is associated with an improvement in survival. External beam radiation traditionally has been offered as the alternative to surgical resection for NSCLC or pulmonary metastatic disease. Unfortunately, the five-year survival following radiation for stage 1 and 2 NSCLC remains low at 15–20 %, with local recurrence being the most common type of failure.1–5

Thermal ablation offers an intriguing therapeutic option to improve local tumour control and survival in patients with early-stage NSCLC or with limited metastatic disease from non-lung primaries who are not candidates for surgical intervention, either because of poor cardiopulmonary reserve, anatomic constraints limiting resection, failure of traditional therapies or refusal of operative approaches. Thermal ablation has been shown to be effective in treating tumours in bone, kidney and liver. This article offers a clinical update on performing thermal ablation in lung tissue and reviews the current literature regarding microwave (MW) ablation therapy in the lung.

The evolving field of pulmonary interventional oncology can only be considered as a small integrative part in the complex area of oncology. The new field of interventional oncology needs adequate knowledge of the therapeutic tools, advantages and limitations of each method, when and how to apply them, as well as of the new integrative protocols that improve their efficacy. In recent years, several new minimally invasive techniques for the non-surgical treatment of lung malignancies, including percutaneous image-guided ablation therapy, have been developed and refined. Since the first reported use of thermal ablation for lung cancer in 2000, there has been a huge increase in the use of the procedure.6–9

To view the full article in PDF or eBook formats, please click on the icons above.

2

References

  1. Greene FL, American Joint Committee on Cancer, American
    Cancer Society, AJCC Cancer Staging Handbook and AJCC Cancer Staging
    Manual, 6th edn, New York: Springer, 2002.

  2. Davidson RS, Nwogu CE, Brentjens MJ, Anderson TM, The
    surgical management of pulmonary metastasis: current
    concepts, Surg Oncol, 2001;10:35–42.

  3. Labow DM, Buell JE, Yoshida A, et al., Isolated pulmonary
    recurrence after resection of colorectal hepatic metastases –
    is resection indicated? Cancer J, 2002;8:342–7.

  4. Sibley GS, Jamieson TA, Marks LB, et al., Radiotherapy alone
    for medically inoperable stage I non-small-cell lung cancer:
    the Duke experience, Int J Radiat Oncol Biol Phys, 1998;40:149–54.

  5. Sirzén F, Kjellén E, Sörenson S, et al., A systematic overview
    of radiation therapy effects in non-small cell lung cancer,
    Acta Oncol, 2003;42:493–515.

  6. McTaggart RA, Dupuy DE, Thermal ablation of lung tumors,
    Tech Vasc Interv Radiol, 2007;10:102–13.

  7. Vogl TJ, Naguib NN, Eichler K, et al., Volumetric evaluation of
    liver metastases after thermal ablation: long-term results
    following MR-guided laser-induced thermotherapy, Radiology,
    2008;249:865–71.

  8. Goldberg SN, Grassi CJ, Cardella JF, et al., Image-guided tumor
    ablation: standardization of terminology and reporting criteria,
    J Vasc Interv Radiol, 2009;20:377–90.

  9. De Baère T, Lung tumor radiofrequency ablation: where do
    we stand? Cardiovasc Intervent Radiol, 2011;34:241–51.

  10. Lencioni R, Crocetti L, Cioni R, et al., Response to
    radiofrequency ablation of pulmonary tumours: a prospective,
    intention-to-treat, multicentre clinical trial (the RAPTURE
    study), Lancet Oncol, 2008;9:621–8.

  11. Hiraki T, Gobara H, Iishi T, Sano Y, Iguchi T, Fujiwara H,
    Tajiri N, Sakurai J, Date H, Mimura H, Kanazawa S,
    Percutaneous radiofrequency ablation for clinical stage I nonsmall
    cell lung cancer: results in 20 nonsurgical candidates,
    J Thorac Cardiovasc Surg, 2007;134:1306–12.

  12. Steinke K, Radiofrequency ablation (RFA). In: Vogl TJ, Helmberger
    TK, Mack MG, Reiser MF (eds), Percutaneous Tumor Ablation in Medical
    Radiology, 1st edn, Berlin, Heidelberg: Springer, 2008;179–96.

  13. Goldberg SN, Radiofrequency tumor ablation: principles and
    techniques, Eur J Ultrasound, 2001;13:129–47.

  14. Helmberger T, Radiofrequency. In: Vogl TJ, Helmberger TK,
    Mack MG, Reiser MF (eds), Percutaneous Tumor Ablation in Medical
    Radiology, 1st edn, Berlin, Heidelberg: Springer, 2008;7–20.

  15. Sharma A, Moore WH, Lanuti M, Shepard JA, How do I do it:
    radiofrequency ablation and cryoablation of lung tumors,
    J Thorac Imaging, 2011;26:162–74.

  16. Hiraki T, Gobara H, Mimura H, et al., Does tumor type affect
    local control by radiofrequency ablation in the lungs?
    Eur J Radiol, 2010;74:136–41.

  17. Simon CJ, Dupuy DE, DiPetrillo TA, et al., Pulmonary
    radiofrequency ablation: long-term safety and efficacy in 153
    patients, Radiology, 2007;243:268–75.

  18. Sonntag PD, Hinshaw JL, Lubner MG, et al., Thermal ablation
    of lung tumors, Surg Oncol Clin N Am, 2011;20:369–87.
    19. Guihaire J, Verhoye JP, de Latour B, Leguerrier A. Parietal
    tumor recurrence of lung metastasis after radiofrequency
    ablation, Interact Cardiovasc Thorac Surg, 2010;10:650–1.

  19. Simon CJ, Dupuy DE, Mayo-Smith WW, Microwave ablation:
    principles and applications, Radiographics, 2005;
    25(Suppl. 1):S69–83.

  20. Boss A, Dupuy D, Pereira PL, Microwave. In: Vogl TJ, Helmberger
    TK, Mack MG, Reiser MF (eds), Percutaneous Tumor Ablation in Medical
    Radiology, 1st edn, Berlin, Heidelberg: Springer, 2008;21–8.

  21. Durick NA, Laeseke PF, Broderick LS, et al., Microwave
    ablation with triaxial antennas tuned for lung: results in an in
    vivo porcine model, Radiology, 2008;247:80–7.

  22. Brace CL, Hinshaw JL, Laeseke PF, et al., Pulmonary thermal
    ablation: comparison of radiofrequency and microwave
    devices by using gross pathologic and CT findings in a swine
    model, Radiology, 2009;251:705–11.

  23. Carrafiello G, Mangini M, De Bernardi I, et al., Microwave
    ablation therapy for treating primary and secondary lung
    tumours: technical note, Radiol Med, 2010;115:962–74.

  24. Wolf FJ, Grand DJ, Machan JT, et al., Microwave ablation of
    lung malignancies: effectiveness, CT findings, and safety in 50
    patients, Radiology, 2008;247:871–9.

  25. Wright AS, Sampson LA, Warner TF, et al., Radiofrequency
    versus microwave ablation in a hepatic porcine model,
    Radiology, 2005;236:132–9.

  26. Vogl TJ, Naguib NN, Gruber-Rouh T, et al., Microwave ablation
    therapy: clinical utility in treatment of pulmonary metastases,
    Radiology, 2011;261:643–51.

  27. Feng W, Liu W, Li C, et al., Percutaneous microwave coagulation
    therapy for lung cancer, Zhonghua Zhong Liu Za Zhi, 2002;24:388–90.

3

Article Information

Disclosure

Thomas J Vogl, Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. E: T.Vogl@em.uni-frankfurt.de

Received

2012-03-02T00:00:00

4

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup